{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:25:33Z","timestamp":1794918333635,"version":"4.9.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41433-018-0289-7","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T07:53:43Z","timestamp":1543478023000},"page":"685-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease"],"prefix":"10.1038","volume":"33","author":[{"given":"Jennifer","family":"Hind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7984-0958","authenticated-orcid":false,"given":"David","family":"Lockington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"289_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575\u2013628.","journal-title":"Ocul Surf"},{"key":"289_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue JS, Figueiredo FC, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26:287\u201396.","journal-title":"Eur J Ophthalmol"},{"key":"289_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5301\/ejo.5000952","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, Figueiredo FC, Messmer EM, Ismail D, Amrane M, Garrigue JS, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27:520\u201330.","journal-title":"Eur J Ophthalmol"},{"key":"289_CR4","first-page":"27","volume":"604204","author":"F Lallemand","year":"2012","unstructured":"Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;604204:27.","journal-title":"J Drug Deliv"},{"key":"289_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/ICL.0000000000000049","volume":"40","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40:289\u201396.","journal-title":"Eye Contact Lens"},{"issue":"1","key":"289_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/bjophthalmol-2017-311801","volume":"103","author":"Andrea Leonardi","year":"2018","unstructured":"Leonardi A, Messmer EM, Labetoulle M, Amrane M, Garrigue JS, Ismail D, et al. Efficacy and safety of 0.1%ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of twodouble-masked, randomised, vehicle-controlled phase III clinical studies. Br JOphthalmol. 2018 Mar 15. pii: bjophthalmol-2017-311801. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311801\n                    \n                  .","journal-title":"British Journal of Ophthalmology"},{"key":"289_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5301\/ejo.5001002","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, de la Maza MS, Amrane M, Garrigue JS, Ismail D, Figueiredo FC, et al. One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27:678\u201385.","journal-title":"Eur J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0289-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:56Z","timestamp":1684616756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-018-0289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["289"],"URL":"https:\/\/doi.org\/10.1038\/s41433-018-0289-7","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]},"assertion":[{"value":"2 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}